UnitedHealth Shares Plunge as Medical Costs Spiral

Investors are sounding the alarm as UnitedHealth Group faces a severe profitability crisis. Despite the healthcare behemoth posting record-breaking revenue figures, its stock value has entered a dramatic downward spiral. The core concern gripping the market is whether the company’s foundational business model remains viable after a disastrous year of trading, or if a complete collapse is imminent.

Profitability Under Siege

The primary driver behind the equity’s sharp decline is a key metric that has investors deeply concerned: the Medical Care Ratio (MCR). For the third quarter of 2025, this figure surged to an alarming 89.9%, marking a significant deterioration from the 85.2% reported in the prior-year period.

This escalation indicates that a progressively larger share of premium revenue is being consumed directly by medical treatment costs. Persistent healthcare inflation and a notable increase in service utilization are eroding the profit margins of the insurance division. While UnitedHealth continues to generate substantial revenue, a shrinking portion is retained as net income—a trend that is severely impacting share performance.

Regulatory and Leadership Turbulence

Compounding the financial distress, the corporation is also contending with significant regulatory challenges. Ongoing investigations by the Department of Justice (DOJ) into its billing practices cast a shadow over the company’s valuation, creating a persistent overhang of uncertainty.

Should investors sell immediately? Or is it worth buying Unitedhealth?

In a move to project stability during this turbulent period—which has also been marked by disruptive leadership changes—the company appointed Dr. Scott Gottlieb, the former FDA commissioner, to its board in November. This is widely seen as a strategic effort to bolster risk management, yet market apprehension remains palpable.

Record Revenue Masks Structural Issues

Paradoxically, the company’s latest operational data underscores its immense market presence. A surface-level review of the growth statistics appears robust:

• Revenue: Jumped to $113.16 billion, a year-over-year increase of 12.2%.
• Earnings Per Share: Came in at $2.92, slightly surpassing analyst forecasts.
• Growth Engine: The Optum services division saw its revenue grow by more than 8%.

However, the market is punishing the stock mercilessly. Investors recognize that this top-line growth is being achieved at an exorbitant cost. There is a pervasive fear that these elevated cost structures could persist well into 2026. Merely exceeding earnings estimates is no longer sufficient to calm the deep-seated anxieties regarding the company’s declining profitability.

The chart performance tells a stark story: with a loss exceeding 42% since the start of the year, the shares are currently trading around 284 euros and are struggling to find a stable floor. Until UnitedHealth can provide concrete evidence that it has halted the relentless rise in costs, any potential recovery is likely to face substantial resistance.